Curaxis Pharmaceutical Corp
Description Curaxis Pharmaceutical Corporation, a development stage specialty pharmaceutical company, focuses on developing a hormone drug product candidate for the treatment of Alzheimers disease and multiple cancers. Its therapeutic platform is based on the hypothesis that various diseases of aging might be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis, a hormonal endocrine feedback loop that controls development, reproduction, and aging in animals. The companys clinical programs include ALADDIN I, which completed Phase II clinical trial to evaluate leuprolide acetate for the treatment of women aged 65 years or older with mild to moderate Alzheimers disease; ALADDIN II, which completed Phase II clinical trial to evaluate leuprolide acetate for the treatment of men aged 65 years or older with mild to moderate Alzheimers disease; and ALADDIN 105 that completed Phase I clinical trial to determine the safety and tolerability of VP4896 implants at various dose combinations on healthy post-menopausal women aged 45 to 70 years and men aged between 50 to 70 years. Curaxis Pharmaceutical Corporation was founded in 2001 and is based in Raleigh, North Carolina. On July 30, 2012, Curaxis Pharmaceutical Corp. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina. To view the detailed information, you need to SUBSCRIBE with us. |
 |